Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 369 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Polyzos, Stergios A [Clear All Filters]
(2019).
Innate immunity and nonalcoholic fatty liver disease..
Ann Gastroenterol. 36(3), 244-256.
(2023). Insulin resistance and therapy: cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways..
Med Hypotheses. 72(5), 610.
(2009). Intracellular leptin signaling following effective weight loss..
Metabolism. 64(8), 888-95.
(2015). The intriguing connections of leptin to hyperparathyroidism..
Endocrine. 57(3), 376-387.
(2017). Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis..
Expert Opin Investig Drugs. 24(2), 145-57.
(2015). Irisin: a renaissance in metabolism?.
Metabolism. 62(8), 1037-44.
(2013). Irisin: A true, circulating hormone..
Metabolism. 64(12), 1611-8.
(2015). Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?.
Metabolism. 93, 100-102.
(2019). Irisin in metabolic diseases..
Endocrine. 59(2), 260-274.
(2018). Irisin in nonalcoholic fatty liver disease: Need for an updated meta-analysis..
Metabolism. 121, 154818.
(2021). Irisin in patients with nonalcoholic fatty liver disease..
Metabolism. 63(2), 207-17.
(2014). Juvenile Paget disease..
Metabolism. 80, 15-26.
(2018). Ki-67 and Bax expression in esophageal mucosa might have implications in ablative therapies for Barrett's esophagus, dysplasia, and adenocarcinoma..
Surg Endosc. 26(1), 283-4.
(2012). Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives..
Cell Metab. 18(1), 29-42.
(2013). Leptin in health and disease: facts and expectations at its twentieth anniversary..
Metabolism. 64(1), 5-12.
(2015). Leptin in nonalcoholic fatty liver disease: a narrative review..
Metabolism. 64(1), 60-78.
(2015). Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals..
Endocr Rev. 34(3), 377-412.
(2013). Letter: Helicobacter pylori in proton pump inhibitor-associated biliary disease..
Aliment Pharmacol Ther. 51(2), 313-314.
(2020). Letter: Helicobacter pylori infection and its role in oesophageal adenocarcinoma..
Aliment Pharmacol Ther. 51(11), 1215-1216.
(2020). Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities..
Aliment Pharmacol Ther. 57(10), 1186-1187.
(2023). Letter: Histological changes among asymptomatic chronic HBV carriers with normal alanine aminotransferase levels..
Aliment Pharmacol Ther. 58(11-12), 1252-1253.
(2023). Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid..
J Clin Endocrinol Metab. 101(9), L89-90.
(2016).
(2024).
(2022).